Document:

Form of Employee Agreement

  
 Exhibit 10.16

 FORM OF EMPLOYMENT AGREEMENT 
 [For Executive Officers other than CEO and President] 
 THIS EMPLOYMENT
AGREEMENT, effective as of                  , 2010, between RICHMOND HONAN MEDICAL PROPERTIES INC., a Maryland corporation (the “Company”),
and                      (the “Executive”), recites and provides as follows: 

W I T N E S S E T H: 

WHEREAS, the Company desires to employ the Executive to devote substantially all of his business time, attention and efforts to
the business of the Company and to serve as the              of the Company; and 
 WHEREAS, the Executive desires to be so employed on the terms and subject to the conditions hereinafter stated. 
 NOW, THEREFORE, in consideration of the premises and mutual obligations hereinafter set forth, the parties agree as follows: 

1. RECITALS. The above recitals are incorporated by reference herein and made a part hereof as set forth verbatim. 

2. EMPLOYMENT. The Company shall employ the Executive, and the Executive agrees to be so employed, in the capacity of the
Company’s              to serve for the Term (as hereinafter defined) hereof, subject to earlier termination as hereinafter provided. 

3. TERM. The Initial Term of the Executive’s employment hereunder (the “Initial Term”) shall be for a period of two
(2) years commencing on                  , 2010, and continuing until             
    , 2012, unless terminated earlier as provided herein. If neither the Company nor the Executive has provided the other with written notice of an intention to terminate this Agreement at least six (6) months before
the end of the Initial Term (or any subsequent renewal period), this Agreement will automatically renew for a twelve (12) month period. For purposes of this Agreement, the word “Term” means the Initial Term and the period of any
extension of the Initial Term pursuant to the preceding sentence. 
 4. SERVICES. The Executive shall devote
substantially all of his business time, attention and effort to the Company’s affairs. The Company further agrees that the Executive may engage in civic, community and religious activities and endeavors provided that such activities do not
interfere with the performance of the Executive’s duties hereunder and may manage the Executive’s personal business endeavors and investments provided that such activities do not interfere with the performance of the Executive’s
duties hereunder and do not violate the Executive’s covenants set forth in Section 16. The Executive shall have full authority and responsibility for formulating policies and administering the Company in all respects, subject to the
general direction, approval and control of the Company’s Chief Executive Officer. 

 5. COMPENSATION. 

(a) Base Salary. During the Term, the Company shall pay the Executive for his services an annual Base Salary equal to
             dollars ($        ), subject to any increases approved by the Board of Directors (the “Board”) or its
Compensation Committee (the “Committee”). Such Base Salary shall be paid in accordance with the Company’s payroll schedule. Any increase in Base Salary shall not serve to limit or reduce any other obligations to the Executive under
this Agreement. 
 (b) Annual Bonus. In addition to his annual Base Salary, beginning in 2011 and during the remainder
of the Term the Executive shall have the opportunity to earn an Annual Bonus to the extent that prescribed individual and corporate goals established by the Committee are achieved. The individual and corporate goals established by the Committee
shall provide the Executive the opportunity to earn Annual Bonus payments of at least twenty-five percent (25%) but not more than one hundred twenty-five percent (125%) of Base Salary to the extent such goals are achieved. Any Annual Bonus
that is earned under this Section 5(b) shall be paid in a single lump sum payment no later than March 15 following the calendar year in which the Annual Bonus is earned. 

6. BENEFITS. The Company agrees to provide the Executive with the following benefits: 

(a) Vacation. The Executive shall be entitled each calendar year to a vacation, during which time his compensation shall be paid
in full. The time allotted for such vacation shall be an aggregate of              (    ) weeks. In the year Executive terminates employment, he shall be
entitled to receive a prorated paid vacation based upon the amount of time that he has worked during the year of termination. In the event that he has not taken his vacation time computed on a prorated basis, he shall be paid, at his regular rate of
pay, for unused vacation. In the event Executive has taken more vacation time than allotted for the year of termination, there shall be no reduction in compensation otherwise payable hereunder. 

(b) Employee Benefits. During the Term, the Executive and/or the Executive’s family, as the case may be, shall be eligible
to participate in all Company employee benefit plans in which other executive level employees of the Company and/or the members of their families, as the case may be, are eligible to participate including, but not limited to, any retirement,
pension, profit-sharing, insurance, hospital, or other plans which may now be in effect or which may hereafter be adopted by the Company. Regarding life insurance, the Executive shall have the right to name the beneficiary of such life insurance
policy. 
 (c) Equity Plan Participation. The Executive shall be eligible to participate in the Company’s 2010
Equity Incentive Plan and any subsequent equity incentive plan established during the Term and shall receive awards, in such amounts and subject to such terms, as determined by the Committee. Notwithstanding the preceding sentence, effective as of
the completion of the initial public offering of the Company’s common stock the Executive shall receive a grant of             
(            ) shares of restricted stock under the Company’s 2010 Equity Incentive Plan which shall vest with respect to 15%, 21%, 28% and 36% of the shares during the second,
third, fourth and fifth years after the date of grant, respectively (subject to the Executive’s continued employment), provide the 
  

 2 

 
Executive the right to receive dividends and vote the outstanding shares of restricted stock and be subject to such other terms as set forth in the award agreement prescribed by the Committee
Such award shall be subject to the terms and conditions of and the Company’s 2010 Equity Incentive Plan). 
 7.
EXPENSES. The Company recognizes that the Executive will have to incur certain out-of-pocket expenses related to his services and the Company’s business, and the Company agrees to promptly reimburse the Executive for all reasonable
expenses necessarily incurred by him in the performance of his duties to the Company upon presentation of a voucher or documentation indicating the amount and business purposes of any such expenses. These expenses include, but are not limited to,
travel, meals, entertainment, etc. Expenses that are reimbursable to the Executive under this Section 7 shall be paid to the Executive in accordance with the Company’s expense reimbursement policy but in no event later than March 15
following the calendar year in which the expense is incurred. 
 8. OFFICE AND SUPPORT STAFF. During the term of this
Agreement, the Executive shall be entitled to an office of a size and with furnishings and other appointments, and to secretarial and other assistants, at least equal to those provided to other management level employees of the Company. 

9. TERMINATION. 
 (a) Grounds. The Executive’s employment shall terminate in the event of the Executive’s death. In the case of the Executive’s Disability, the Company may elect to terminate the
Executive’s employment as a result of such Disability. Where appropriate, the Company also may terminate the Executive’s employment pursuant to a Termination With Cause. Finally, the Executive may terminate his employment with the Company
pursuant to either a Voluntary Termination or a Voluntary Termination for Good Reason. For purposes of this Agreement, the terms Disability, Voluntary Termination, Voluntary Termination for Good Reason, and Termination With Cause are defined in
Section 12 of this Agreement. 
 (b) Notice of Termination. Any termination by the Company or the Executive (other
than upon death) shall be communicated by Notice of Termination to the Executive or the Company, as applicable. For purposes of this Agreement, a “Notice of Termination” means a written notice which (i) indicates the specific
termination provision in this Agreement relied upon and the specific ground for termination; (ii) sets forth in reasonable detail the facts and circumstances claimed to provide a basis for such termination; and (iii) the date of
termination in accordance with Section 9(c) below. 
 (c) Date of Termination. For the purposes of this Agreement,
“Date of Termination” means (i) if the Company intends to treat the termination as a termination based upon the Executive’s Disability, the Executive’s employment with the Company shall terminate effective on the thirtieth
day after the date of the Notice of Termination (which may not be given before the Executive has been absent from work on account of a physical or mental illness or physical injury for at least [one hundred fifty (150) days)] provided that,
before such date, the Executive shall not have returned to full-time performance of the Executive’s duties; (ii) if the Executive’s employment is terminated by reason of Death, the Date of Termination shall be the

  

 3 

 
date of death of the Executive; (iii) if the Executive’s employment is terminated by reason of Voluntary Termination, the Date of Termination shall be thirty (30) days from the
date of the Notice of Termination (and the Executive shall be deemed to have terminated his employment by Voluntary Termination if the Executive voluntarily refuses to provide substantially all the services described in Section 4 hereof for a
period greater than four (4) consecutive weeks (excluding periods in which the Executive is not performing services on account of vacation in accordance with Section 6(a) hereof and periods in which the Executive is not performing services
on account of the Executive’s illness or injury or the illness or injury of a member of the Executive’s immediate family); in such event, the Date of Termination shall be the day after the last day of such four-week period); (iv) if
the Company intends to treat the termination as a Termination With Cause, the Company shall provide the Executive Notice of Termination specifying the grounds for termination and the Executive shall have a period of thirty (30) days to cure
such cause to the reasonable satisfaction of a majority of the Independent Directors (as defined in Section 12(b)), failing which employment shall be deemed terminated at the end of such thirty (30) day period and the last day of such
thirty (3) day period shall be the Date of Termination or (v) if the Executive’s employment is terminated by reason of Voluntary Termination for Good Reason, the Date of Termination shall be thirty (30) days after the end of the
thirty (30) day cure period. 
 10. COMPENSATION UPON TERMINATION WITH CAUSE, VOLUNTARY TERMINATION, DEATH OR
DISABILITY. This Section 10 applies in the event that the Executive’s employment ends upon a Termination With Cause, a Voluntary Termination, Death or Disability or any reason other than a Termination Without Cause or a Voluntary
Termination With Good Reason. In any of those events, the Executive (or the Executive’s estate in the event of his death) shall be entitled to receive the Standard Termination Benefits. The Standard Termination Benefits are the benefits or
amounts described in the following subsections (a) and (b): 
 (a) The Executive shall be entitled to receive any
compensation (including Base Salary and Annual Bonus and accrued but unused vacation) that is earned but unpaid as of the Date of Termination. 
 (b) The Executive shall be entitled to receive any benefits due him under the terms of any employee benefit plan maintained by the Company and under the terms of any option, restricted stock or similar
equity award; which benefits shall be paid in accordance with the terms of the applicable plan and any award agreement between the Executive and the Company. 
 Except for the Standard Termination Benefits, the Executive shall not be entitled to receive any compensation after the Date of Termination on account of a Termination With Cause, a Voluntary Termination,
death, Disability or any reason other than a Termination Without Cause or a Voluntary Termination With Good Reason. 
  

 4 

 11. COMPENSATION UPON TERMINATION WITHOUT CAUSE OR VOLUNTARY TERMINATION WITH GOOD
REASON. This Section 11 applies in the event that the Executive’s employment ends upon a Termination Without Cause or a Voluntary Termination With Good Reason. In any of those events, the Executive shall be entitled to receive the
benefits and amounts described in the following subsections (a), (b), (c) and (d): 
 (a) The Company shall pay or provide
the Standard Termination Benefits as defined in Section 10 except that all outstanding options, shares of restricted stock and other equity awards, shall be vested and exercisable as of the Date of Termination and outstanding options, stock
appreciation rights and similar equity awards shall remain exercisable thereafter until their stated expiration date as if the Executive’s employment had not terminated. 
 (b) The Company shall pay an amount equal to two (2) times the Executive’s Base Salary at the rate in effect on the Date of Termination (or, in the case of a Voluntary Termination for Good
Reason, at the rate in effect before a reduction in Base Salary that constitutes Good Reason for resignation), such payment to be made in a single cash payment. 
 (c) The Company shall pay an amount equal to two (2) times the greater of the highest annual bonus paid to the Executive for the three (3) fiscal years of the Company ended immediately before
the Date of Termination and twenty-five percent (25%) of the Executive’s Base Salary, at the rate in effect on the Date of Termination (or, in the event of a Voluntary Termination for Good Reason, at the rate in effect before a reduction
in Base Salary that constitutes Good Reason for resignation), such payment to be made in a single cash payment. 
 (d) The
Company shall pay an amount equal to the product of (x) the Annual Bonus earned by the Executive for the fiscal year of the Company ended immediately before the Date of Termination and (y) a fraction, the numerator of which
is the number of days the Executive was employed by the Company during the fiscal year that includes the Date of Termination and the denominator of which is 365, such payment to be made in a single cash payment. 

(e) The Company shall pay an amount equal to two (2) times the annual premium or cost paid by the Company for the health, dental
and vision insurance coverage for the Executive and the Executive’s eligible dependents as in effect on the Date of Termination plus an amount equal to two (2) times the annual premium or cost paid by the Company for the disability and
life insurance coverage for the Executive as in effect on the Date of Termination, such payment to be made in a single cash payment. 
 Except for the Standard Termination Benefits, no benefits will be paid or provided to, or on behalf of, the Executive under this Section 11 unless the Executive has signed a release and waiver of
claims in a form reasonably prescribed by the Company (which shall be provided to the Executive by the Company within three (3) days after the Date of Termination), releasing the Company and its officers, directors and affiliates from all
claims the Executive has or may have against such parties, and such release and waiver of claims has become binding and irrevocable on or before the forty-fifth (45th) day after the date the Executive’s employment ends upon a Termination Without Cause or a Voluntary
Termination for Good Reason. Subject to the Executive’s satisfaction of the requirements of the preceding sentence and subject to Section 14, the cash benefits payable under this Section 11 shall be paid on the sixtieth (60th) day after the Executive’s employment ends upon a
Termination Without Cause or a Voluntary Termination for Good Reason. 
  

 5 

 12. DEFINITIONS. For the purposes of this Agreement, the following terms shall have
the following definitions: 
 (a) “Disability” means that the Executive is “disabled” within the
meaning of Section 409A(a)(2)(C) of the Internal Revenue Code of 1986, as amended (the “Code”). 
 (b)
“Termination With Cause” means the termination of the Executive’s employment by act of the Company’s Board of Directors on account of (i) the Executive’s repeated and continuing (x) failure to perform
a material duty of the Executive’s employment, (y) the Executive’s material breach of an obligation set forth in this Agreement or (z) breach of a material and written Company policy in each case other than by
reason of mental or physical illness or injury, (ii) the Executive’s breach of Executive’s fiduciary duties to the Company, (iii) the Executive’s conduct that is demonstrably and materially injurious to the Company,
monetarily or otherwise or (iv) the Executive’s conviction of, or plea of nolo contendre to, a felony or crime involving moral turpitude or fraud or dishonesty involving assets of the Company and that in all cases is described in a
written notice adopted and approved by a majority of the non-employee members of the Board (the “Independent Directors”) and that is not cured, to the reasonable satisfaction of a majority of the Independent Directors within thirty
(30) days after such notice is received by the Executive. 
 (c) “Voluntary Termination” means the
Executive’s voluntary termination of his employment hereunder for any reason other than a Voluntary Termination for Good Reason. For purposes of this Section 12, the term Voluntary Termination does not include a voluntary refusal to
perform services on account of a vacation taken in accordance with Section 6(a) hereof, the Executive’s failure to perform services on account of his illness or injury or the illness or injury of a member of his immediate family, provided
such illness is adequately substantiated at the reasonable request of the Company, or any other absence from service with the written consent of the Board. 
 (d) Voluntary Termination for “Good Reason” means the Executive’s termination of his employment hereunder on account of (i) the Company’s material breach of the terms of
this Agreement or a direction from the Board that the Executive act or refrain from acting which in either case would be unlawful or contrary to a material and written Company policy, (ii) a material diminution in the Executive’s duties,
functions and responsibilities to the Company and its subsidiaries without the Executive’s consent or the Company preventing the Executive from fulfilling or exercising his material duties, functions and responsibilities to the Company and its
subsidiaries without the Executive’s consent, (iii) a material reduction in the Executive’s Base Salary or Annual Bonus opportunity or (iv) a requirement that the Executive relocate his employment more than fifty (50) miles
from the location of the Executive’s principal office on the date of this Agreement, without the consent of the Executive. The Executive’s resignation shall not be deemed a “Voluntary Termination for Good Reason” unless the
Executive gives the Board written notice (delivered within thirty (30) days after the Executive knows of the event, action, etc. that the Executive asserts constitutes Good Reason), the event, action, etc. that the Executive asserts constitutes
Good Reason is not cured, to the reasonable satisfaction of the Executive, within thirty (30) days after such notice and the Executive resigns effective not later than ninety (90) days after the expiration of such cure period. 

 

 6 

 13. CODE SECTION 280G. The benefits that the Executive may be entitled to receive
under this Agreement and other benefits that the Executive is entitled to receive under other plans, agreements and arrangements (which, together with the benefits provided under this Agreement, are referred to as “Payments”), may
constitute Parachute Payments that are subject to Code Sections 280G and 4999. As provided in this Section 13, the Parachute Payments will be reduced if, and only to the extent that, a reduction will allow the Executive to receive a greater Net
After Tax Amount than the Executive would receive absent a reduction. 
 The Accounting Firm will first determine the amount of
any Parachute Payments that are payable to the Executive. The Accounting Firm also will determine the Net After Tax Amount attributable to the Executive’s total Parachute Payments. 

The Accounting Firm will next determine the largest amount of Payments that may be made to the Executive without subjecting the Executive
to tax under Code Section 4999 (the “Capped Payments”). Thereafter, the Accounting Firm will determine the Net After Tax Amount attributable to the Capped Payments. 

The Executive will receive the total Parachute Payments or the Capped Payments, whichever provides the Executive with the higher Net
After Tax Amount. If the Executive will receive the Capped Payments, the total Parachute Payments will be adjusted by first reducing the amount of any benefits under this Agreement or any other plan, agreement or arrangement that are not subject to
Section 409A of the Code (with the source of the reduction to be directed by the Participant) and then by reducing the amount of any benefits under this Agreement or any other plan, agreement or arrangement that are subject to Section 409A
of the Code (with the source of the reduction to be directed by the Participant). The Accounting Firm will notify the Executive and the Company if it determines that the Parachute Payments must be reduced to the Capped Payments and will send the
Executive and the Company a copy of its detailed calculations supporting that determination. 
 As a result of the uncertainty
in the application of Code Sections 280G and 4999 at the time that the Accounting Firm makes its determinations under this Section 13, it is possible that amounts will have been paid or distributed to the Executive that should not have been
paid or distributed under this Section 13 (“Overpayments”), or that additional amounts should be paid or distributed to the Executive under this Section 13 (“Underpayments”). If the Accounting Firm determines, based on
either the assertion of a deficiency by the Internal Revenue Service against the Company or the Executive, which assertion the Accounting Firm believes has a high probability of success or controlling precedent or substantial authority, that an
Overpayment has been made, the Executive must repay to the Company, without interest; provided, however, that no loan will be deemed to have been made and no amount will be payable by the Executive to the Company unless, and then only to the extent
that, the deemed loan and payment would either reduce the amount on which the Executive is subject to tax under Code Section 4999 or generate a refund of tax imposed under Code Section 4999. If the Accounting Firm determines, based upon
controlling precedent or substantial authority, that an Underpayment has occurred, the Accounting Firm will notify the Executive and the Company of that determination and the amount of that Underpayment will be paid to the Executive promptly by the
Company. 
  

 7 

 For purposes of this Section 13, the term “Accounting Firm” means the
independent accounting firm engaged by the Company immediately before the change in control. For purposes of this Section 13, the term “Net After Tax Amount” means the amount of any Parachute Payments or Capped Payments, as
applicable, net of taxes imposed under Code Sections 1, 3101(b) and 4999 and any State or local income taxes applicable to the Executive on the date of payment. The determination of the Net After Tax Amount shall be made using the highest combined
effective rate imposed by the foregoing taxes on income of the same character as the Parachute Payments or Capped Payments, as applicable, in effect on the date of payment. For purposes of this Section 13, the term “Parachute Payment”
means a payment that is described in Code Section 280G(b)(2), determined in accordance with Code Section 280G and the regulations promulgated or proposed thereunder. 
 14. CODE SECTION 409A. This Agreement and the amounts payable and other benefits provided under this Agreement are intended to comply with, or otherwise be exempt from, Section 409A of
the Code (“Section 409A”), after giving effect to the exemptions in Treasury Regulation section 1.409A-1(b)(3) through (b)(12). This Agreement shall be administered, interpreted and construed in a manner consistent with Section 409A.
If any provision of this Agreement is found not to comply with, or otherwise not be exempt from, the provisions of Section 409A, it shall be modified and given effect, in the sole discretion of the Board and without requiring the
Executive’s consent, in such manner as the Board determines to be necessary or appropriate to comply with, or to effectuate an exemption from, Section 409A; provided, however, that in exercising its discretion under this Section 14,
the Board shall modify this Agreement in the least restrictive manner necessary and without reducing any payment or benefit due under this Agreement. Each payment under this Agreement shall be treated as a separate identified payment for purposes of
Section 409A. 
 With respect to any reimbursement of expenses of, or any provision of in-kind benefits to, the Executive,
as specified under this Agreement, such reimbursement of expenses or provision of in-kind benefits shall be subject to the following limitations: (i) the expenses eligible for reimbursement or the amount of in-kind benefits provided in one
taxable year shall not affect the expenses eligible for reimbursement or the amount of in-kind benefits provided in any other taxable year, except for any medical reimbursement arrangement providing for the reimbursement of expenses referred to in
Section 105(b) of the Code; (ii) the reimbursement of an eligible expense shall be made as specified in this Agreement and in no event later than the end of the year after the year in which such expense was incurred and (iii) the
right to reimbursement or in-kind benefit shall not be subject to liquidation or exchange for another benefit. 
 If a payment
obligation under this Agreement arises on account of a change in control or the Executive’s termination of employment and such payment obligation constitutes “deferred compensation” (as defined under Treasury Regulation section
1.409A-1(b)(1), after giving effect to the exemptions in Treasury Regulation section 1.409A-1(b)(3) through (b)(12)), it shall be payable only if the change in control constitutes a change in ownership or effective control of the Company, etc. as
provided in Treasury Regulation section 1.409A-3(i)(5) or after the 
  

 8 

 
Executive’s separation from service (as defined under Treasury Regulation section 1.409A-1(h)); provided, however, that if the Executive is a specified employee (as defined under Treasury
Regulation section 1.409A-1(i)), any payment that is scheduled to be paid within six months after such separation from service shall accrue without interest and shall be paid on the first day of the seventh month beginning after the date of the
Executive’s separation from service or, if earlier, within fifteen days after the appointment of the personal representative or executor of the Executive’s estate following his death. 

15. TAX WITHHOLDING. All payments to be made under this Agreement shall be reduced by applicable income and employment tax
withholdings. 
 16. COVENANTS OF THE EXECUTIVE. 

(a) General Covenants of the Executive. The Executive acknowledges that (i) the principal business of the Company is the
acquisition, ownership, management, development and re-development of medical office buildings by the Company or one or more of the Company’s subsidiaries (such business herein being collectively referred to as the “Business”),
(ii) the Executive is one of a limited number of persons who have developed the Business; (iii) the Business is, in part, national in scope; (iv) the Executive’s work for the Company has given and will continue to give the
Executive access to, and the Company has entrusted and will continue to entrust the Executive with, the confidential affairs and proprietary information of the Company, including, but not limited to, the strategies, future plans, financial and
customer data and “trade secrets,” as defined in O.C.G.A. § 10-1-760, et seq., of the Company and its subsidiaries; (v) the covenants and agreements of the Executive contained in this Section 16 are essential to
the business and goodwill of the Company; and (vi) the Company would not have entered into this Agreement but for the covenants and agreements set forth in this Section 16. 

(b) Covenant Against Competition. The covenant against competition herein described shall apply during the Term and for a period
of eighteen (18) months following a termination of the Executive’s employment with the Company and its subsidiaries for any reason (the “Restriction Period”). During the Restriction Period the Executive shall not, directly or
indirectly, own, manage, control or participate in the ownership, management, or control of, or be employed or engaged by or otherwise affiliated or associated with, in an executive, senior management, strategic or professional capacity, whether as
an employee, employer, consultant, agent, principal, partner, stockholder, corporate officer, director or in any other individual or representative capacity, that is similar to an engagement in an executive, senior management, strategic or
professional capacity although otherwise named, any business or venture that owns, manages, develops or re-develops medical office buildings within twenty-five (25) miles of any medical office building owned, managed, developed or re-developed
by the Company or its subsidiary, or any business or venture that owns, manages, develops or re-develops medical office buildings within twenty-five (25) miles of any medical office building the Company is pursuing to acquire, own, manage,
develop or re-develop so long as the pursuit of such began prior to, and remained ongoing at the time of the termination of the Executive’s employment; provided, however, that, notwithstanding the foregoing, the Executive may
invest in securities of any entity, solely for investment purposes and without participating in the business thereof, if (A) such securities are traded on any national securities exchange or the National Association of

  

 9 

 
Securities Dealers, Inc. Automated Quotation System or equivalent non-U.S. securities exchange, (B) the Executive is not a controlling person of, or a member of a group which controls, such
entity and (C) the Executive does not, directly or indirectly, own [one percent (1%)] or more of any class of securities of such entity. 
 (c) Confidentiality. During and after the Executive’s employment with the Company and its subsidiaries, except in connection with the business and affairs of the Company and its subsidiaries:
the Executive shall keep secret and retain in strictest confidence, and shall not use for his benefit or the benefit of others, all confidential matters relating to the Business and the business of the Company and its subsidiaries, learned by the
Executive heretofore or hereafter directly or indirectly from the Company of any of its subsidiaries (or any predecessor of either) (the “Confidential Company Information”), including, without limitation, information with respect to
the Business and any aspect thereof, profit or loss figures, and the Company’s or its subsidiaries’ (or any of their predecessors) properties, and shall not disclose such Confidential Company Information to anyone outside of the Company
except with the Company’s express written consent and except for Confidential Company Information which (i) at the time of receipt or thereafter becomes publicly known through no wrongful act of the Executive; (ii) is clearly
obtainable in the public domain; (iii) was not acquired by the Executive in connection with the Executive’s employment or affiliation with the Company; (iv) was not acquired by the Executive from the Company or its representatives or
from a third-party who has an agreement with the Company not to disclose such information; (v) was legally in the possession of or developed by the Executive prior to the Effective Date; or (vi) is required to be disclosed by rule of law
or by order of a court or governmental body or agency. Notwithstanding the foregoing, as to confidential information that is not a trade secret under O.C.G.A. § 10-1-760, et seq., the covenants contained in this Section 16(c)
shall expire on the second anniversary of the termination of the Executive’s employment with the Company and its subsidiaries. Company trade secrets, as defined in O.C.G.A. § 10-1-760, et seq., shall remain protected and not be
disclosed so long as they remain trade secrets. 
 (d) Nonsolicitation. During the Restriction Period the Executive
shall not, without the Company’s prior-written consent, directly or indirectly, (i) knowingly solicit or knowingly encourage to leave the employment or other service of the Company or any of its subsidiaries, any employee employed by the
Company on the date the Executive’s employment with the Company and its subsidiaries terminates or knowingly hire (on behalf of the Executive or any other person or entity) any employee employed by the Company or a subsidiary on the date the
Executive’s employment with the Company and its subsidiaries terminates who has left the employment or other service of the Company or any of its subsidiaries (or any predecessor of either) within six (6) months of the termination of such
employee’s or independent contractor’s employment or other service with the Company and its subsidiaries; provided that this clause (i) shall not apply to the solicitation or employment of members of the Executive’s immediate
family (i.e., parent, stepparent, child (including an adopted child) or stepchild) who is not a senior executive officer of the Company; or (ii) whether for the Executive’s own account or for the account of any other person, firm,
corporation or other business organization, intentionally interfere with the Company’s or any of its subsidiaries’, relationship with, or endeavor to entice away from the Company or any of its subsidiaries, any person who during the
Executive’s employment with the Company is or was a customer or client of the Company or any of its subsidiaries (or any predecessor of either) with whom the Executive had Material Contact on

  

 10 

 
behalf of the Company within one (1) year prior to the termination of the Executive’s Employment with the Company and its subsidiaries. “Material Contact” shall mean contact
whereby (i) the Executive had business dealings with the person, entity, customer or supplier on the Company’s behalf; (ii) the Executive was responsible for supervising or coordinating the dealings between the person, entity,
customer or supplier and the Company; or (iii) the Executive obtained Confidential Company Information about the person, entity, customer or supplier as a result of the Executive’s association with the Company and its subsidiaries.
Notwithstanding the above, nothing shall prevent the Executive from soliciting loans, investment capital, or the provision of management services from third parties engaged in the Business if the activities of the Executive facilitated thereby do
not otherwise adversely interfere with the operations of the Business. 
 (e) Company Property. During and after the
Executive’s employment with the Company and its subsidiaries, all memoranda, notes, lists, records, property and any other tangible product and documents (and all copies thereof) made, produced or compiled by the Executive or made available to
the Executive during the Term concerning the Business of the Company and its subsidiaries shall be the Company’s property and shall be delivered to the Company at any time on request. Notwithstanding the above, the Executive’s contacts and
contact data base shall not be the Company’s property. Notwithstanding the above, software, methods and material developed by the Executive prior to the Term of the Agreement shall not be the Company’s property. 

(f) Rights and Remedies upon Breach. The Executive acknowledges and agrees that any breach by him of any of the provisions of
this Section 16 (the “Covenants”) would result in irreparable injury and damage for which money damages, would not provide an adequate remedy. Therefore, if the Executive breaches, or threatens to commit a breach of, any of the
Covenants, the Company and its subsidiaries shall have the right and remedy to have the Covenants specifically enforced (without posting bond and without the need to prove damages) by any court having equity jurisdiction, including, without
limitation, the right to an entry against the Executive of restraining orders and injunctions (preliminary, mandatory, temporary and permanent) against violations, threatened or actual, and whether or not then continuing, of such covenants. This
right and remedy shall be in addition to, and not in lieu of, any other rights and remedies available to the Company and its subsidiaries under law or in equity (including, without limitation, the recovery of damages). The existence of any claim or
cause of action by the Executive, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement of the Covenants. The Company has the right to cease making the payments or benefits to the Executive in the event
of a material breach of any of the Covenants that, if capable of cure and not willful, is not cured within thirty (30) days after receipt of notice thereof from the Company. 

(g) Severability. The Executive acknowledges and agrees that the Executive has had an opportunity to seek advice of counsel in
connection with this Agreement; and that the Covenants are reasonable in geographical and temporal scope and in all other respects. If it is determined that any of the provisions of this Agreement, including, without limitation, any of the
Covenants, or any part thereof, is invalid or unenforceable, the remainder of the provisions of this Agreement shall not thereby be affected and shall be given full affect, without regard to the invalid portions. 

 

 11 

 (h) Duration and Scope of Covenants. If any court or other decision maker of
competent jurisdiction determines that any of the Covenants, including, without or any part thereof are unenforceable because of the duration or geographical scope of such provision, then, after such determination has become final and unappealable,
the duration or scope of such provision, as the case may be, shall be reduced so that such provision becomes enforceable and, in its reduced form, such provision shall then be enforceable and shall be enforced. 

(i) Enforceability of Restrictive Covenants; Jurisdictions. The Company and the Executive intend to and hereby consent to
jurisdiction to enforce the Covenants upon the courts of any jurisdiction within the geographical scope of the Covenants, including, but not limited to, the State of Georgia. If the courts of any one or more of such jurisdictions hold the Covenants
wholly unenforceable by reason of breadth of scope or otherwise it is the intention of the Company and the Executive that such determination not bar or in any way affect the Company’s right, or the right of any of its affiliates, to the relief
provided above in the courts of any other jurisdiction within the geographical scope of such Covenants, as to breaches of such Covenants in such other respective jurisdictions, such Covenants as they relate to each jurisdiction’s being, for
this purpose, severable, diverse and independent covenants, subject, where appropriate, to the laws of the State of Georgia. 

17. NOTICES. All notices or deliveries authorized or required pursuant to this Agreement shall be deemed to have been given when
in writing and personally delivered or three (3) days following the date when deposited in the U.S. mail, certified, return receipt requested, postage prepaid, addressed to the parties at the following addresses or to such other addresses as
either may designate in writing to the other party: 
  

									
		 	 To the Company:
	 		  	RICHMOND HONAN MEDICAL PROPERTIES INC.
					
		 		 		  	Attn:	 	  

		 		 		  	975 Johnson Ferry Road, Suite 450
		 		 		  	Atlanta, GA, 30342
				
		 	 To the Executive:
	 		  	[NAME]
				
		 		 		  	  

				
		 		 		  	  

				
		 		 		  	  

18. ENTIRE AGREEMENT. This Agreement contains the entire understanding between the parties hereto with respect to the subject
matter hereof and shall not be modified in any manner except by instrument in writing signed, by or on behalf of, the parties hereto. This Agreement shall be binding upon and inure to the benefit of the heirs, successors and assigns of the parties
hereto. 
 19. ARBITRATION. Any claim or controversy arising out of, or relating to, this Agreement or its breach, shall
be settled by arbitration in Atlanta, Georgia in accordance with the governing rules of the American Arbitration Association. Judgment upon the award rendered may be entered in any court of competent jurisdiction. In the event one of the parties
hereto requests an arbitration proceeding under this Agreement, such proceeding shall commence within 30 days from the date of such request. 

  
 12 

  
 20. APPLICABLE
LAW. This Agreement shall be governed and construed in accordance with the laws of the State of Georgia. 
 21. NO
SETOFF. The Company’s obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by a setoff, counterclaim, recoupment, defense or other claim, right or action
which the Company may have against the Executive or others. In no event shall the Executive be obligated to seek other employment or take other action by way of mitigation of the amounts payable to the Executive under the provisions of this
Agreement. 
 22. ASSIGNMENT. The Executive acknowledges that his services are unique and personal. Accordingly, the
Executive may not assign his rights or delegate his duties or obligations under this Agreement. The Executive’s rights and obligations under this Agreement shall insure to the benefit of and shall be binding upon the Executive’s successors
and assigns. 
 23. HEADINGS. Headings in this Agreement are for convenience only and shall not be used to interpret or
construe its provisions. 
 24. SURVIVAL. The provisions of Section 13 through 23 shall remain in effect after the
expiration of the Term and the termination of the Executive’s employment. 
 IN WITNESS WHEREOF, the parties have executed
this Agreement as of the      day of             , 2010. 

 

			
	RICHMOND HONAN MEDICAL PROPERTIES INC.,
	a Maryland real estate investment trust
		
	 By:
	 	  

		 	 Title:

	
	[EXECUTIVE]
		
		 	  

  
 13Form of Tax Protection Agreement

  
 Exhibit 10.17

 FORM OF TAX PROTECTION AGREEMENT 
 THIS TAX PROTECTION AGREEMENT (this “Agreement”) is made and entered into as of             , 2010 by and among RICHMOND HONAN
MEDICAL PROPERTIES INC., a Maryland corporation (the “REIT”), RICHMOND HONAN MEDICAL PROPERTIES LP, a Delaware limited partnership (the “Partnership”), and RICHMOND 400, Ltd., a Georgia limited partnership (the “Merging
Entity”). 
 WHEREAS, pursuant to that certain Merger Agreement, dated as of
            , 2010, (the “Merger Agreement”), the Merging Entity will merge into a subsidiary of the Partnership, with the subsidiary of the Partnership surviving, with
certain of the members of the Merging Entity exchanging their interests in the Merging Entity for common partnership units of limited partnership interest in the Partnership (“Units”), cash or a combination of cash and Units; 

WHEREAS, it is intended for federal income tax purposes that the Merger will treated as an “assets over form” merger, as
prescribed by Treasury Regulations Sections 1.708-1(c)(3)(i) and 1.708-1(c)(4); 
 WHEREAS, in accordance with
Section 7.2(e) of the Merger Agreement and in consideration for the agreement of the Merging Entity to consummate the Merger, the parties desire to enter into this Agreement regarding certain tax matters as set forth herein; and 

WHEREAS, the REIT and the Partnership desire to evidence their agreement regarding amounts that may be payable in the event of certain
actions being taken by the Partnership regarding the disposition of certain of the contributed assets and certain debt obligations of the Partnership and its subsidiaries. 
 NOW, THEREFORE, in consideration of the premises and the mutual representations, warranties, covenants and agreements contained herein and in the Merger Agreement, the parties hereto hereby agree as
follows: 
 ARTICLE 1 
 DEFINITIONS 
 To the extent not otherwise defined herein, capitalized terms
used in this Agreement have the meanings ascribed to them in the Partnership Agreement (as defined below). 
 “Cash
Consideration” has the meaning set forth in Section 2.1(a). 
 “Closing Date” means the
date on which the Merger will be effective. 
 “Code” means the Internal Revenue Code of 1986, as amended.

 “Consent” means the prior written consent to do the act or thing for which the consent is required or
solicited, which consent may be executed by a duly authorized officer or agent of the party granting such consent. 

  
 “Gain
Limitation Property” means (i) each of the properties identified on Schedule 2.1(b) hereto as a Gain Limitation Property; (ii) any other property or asset hereafter acquired by the Partnership or any direct or indirect
interest owned by the Partnership in any entity that owns an interest in a Gain Limitation Property, if the disposition of that property or asset would result in the recognition of Protected Gain by a Protected Partner; and (iii) any other
property that the Partnership directly or indirectly receives that is in whole or in part a “substituted basis property” as defined in Section 7701(a)(42) of the Code with respect to a Gain Limitation Property. 

“Guaranteed Amount” means the aggregate amount of each Guaranteed Debt that is guaranteed at any time by Partner
Guarantors. 
 “Guaranteed Debt” means any loans incurred (or assumed) by the Partnership or any of its
subsidiaries that are guaranteed by Partner Guarantors at any time after the Closing Date pursuant to Article 3 hereof. 

“Indirect Owner” means, in the case of a Protected Partner that is an entity that is classified as a partnership,
disregarded entity or subchapter S corporation for federal income tax purposes, any person owning an equity interest in such Protected Partner, and in the case of any Indirect Owner that itself is an entity that is classified as a partnership,
disregarded entity or subchapter S corporation for federal income tax purposes, any person owning an equity interest in such entity. 
 “Minimum Liability Amount” means, for each Protected Partner, the amount set forth next to such Protected Partner’s name on Schedule 3.2(a) hereto. 

“Nonrecourse Liability” has the meaning set forth in Treasury Regulations Section 1.752-1(a)(2). 

“Partner Guarantors” means those Protected Partners who have guaranteed any portion of the Guaranteed Debt. 

“Partnership” has the meaning set forth in the Preamble. 

“Partnership Agreement” means the Amended and Restated Agreement of Limited Partnership of the Partnership, dated as of
            , 2010, as amended, and as the same may be further amended in accordance with the terms thereof. 
 “Partnership Interest Consideration” has the meaning set forth in Section 2.1(a). 
 “Protected Gain” shall mean the gain that would be allocable to and recognized by a Protected Partner under Section 704(c) of the Code in the event of the sale of a Gain Limitation
Property in a fully taxable transaction. The initial amount of Protected Gain with respect to each Protected Partner shall be determined as if the Partnership sold each Gain Limitation Property in a fully taxable transaction on the Closing Date for
consideration equal to the Section 704(c) Value of such Gain Limitation Property on the Closing Date, and is set forth on Schedule 2.1(b) hereto. Gain that would be allocated to a Protected Partner upon a sale of a Gain Limitation
Property that is “book gain” (for example, any gain attributable to appreciation 

  
 2 

 
in the actual value of the Gain Limitation Property following the Closing Date or any gain resulting from reductions in the “book value” of the Gain Limitation Property following the
Closing Date) shall not be considered Protected Gain. (As used in this definition, “book gain” is any gain that would not be required under Section 704(c) of the Code and the applicable regulations to be specially allocated to the
Protected Partners, but rather would be allocated to all partners in the Partnership, including the REIT, in accordance with their respective economic interests in the Partnership.) 

“Protected Partner” means those persons set forth as Protected Partners on Schedule 2.1(a), and any person who
(i) acquires Units from a Protected Partner in a transaction in which gain or loss is not recognized in whole or in part and in which such transferee’s adjusted basis for federal income tax purposes is determined in whole or in part by
reference to the adjusted basis of the Protected Partner in such Units, (ii) has notified the Partnership of its status as a Protected Partner and (iii) provides all documentation reasonably requested by the Partnership to verify such
status, but excludes any person that ceases to be a Protected Partner pursuant to this Agreement. 
 “Section 704(c)
Value” means the fair market value of any Gain Limitation Property as of the Closing Date, as determined by the Partnership and as set forth next to each Gain Limitation Property on Schedule 2.1(b) hereto. The Partnership shall
initially carry the Gain Limitation Property on its books at a value equal to the Section 704(c) Value as set forth in the preceding sentence. 
 “Subsidiary” means any entity in which the Partnership owns a direct or indirect interest that owns a Gain Limitation Property on the Closing Date, after giving effect to the Merger, or
that thereafter is a successor to the Partnership’s direct or indirect interests in a Gain Limitation Property. 

“Successor Partnership” has the meaning set forth in Section 2.1(b). 

“Tax Protection Period” means the period commencing on the Closing Date and ending at 12:01 AM on
            2020, provided, however, that with respect to a Protected Partner, the Tax Protection Period shall terminate at such time as such Protected Partner (or one
or more successor Protected Partners) has disposed of 80% or more of the Units received, directly or indirectly, in the Merger by such Protected Partner in one or more taxable transactions. 

“Units” has the meaning set forth in the Recitals. 

ARTICLE 2 

RESTRICTIONS ON DISPOSITIONS OF 
 GAIN LIMITATION PROPERTIES 
 2.1 Restrictions on Disposition of Gain
Limitation Properties. 
 (a) The Partnership agrees for the benefit of each Protected Partner, for the term of the Tax
Protection Period, not to directly or indirectly sell, exchange, transfer, or otherwise dispose of a Gain Limitation Property or any interest therein, without regard to whether such disposition is voluntary or involuntary, in a transaction that
would cause any Protected Partner to recognize any Protected Gain. 

  
 3 

  
 Without limiting the
foregoing, the term “sale, exchange, transfer or disposition” by the Partnership shall be deemed to include, and the prohibition shall extend to: 
  

	 	(i)	any direct or indirect disposition by any direct or indirect Subsidiary of any Gain Limitation Property or any interest therein; 

 

	 	(ii)	any direct or indirect disposition by the Partnership of any Gain Limitation Property (or any direct or indirect interest therein) that is subject to
Section 704(c)(1)(B) of the Code and the Treasury Regulations thereunder; and 

  

	 	(iii)	any distribution by the Partnership to a Protected Partner that is subject to Section 737 of the Code and the Treasury Regulations thereunder.

 Without limiting the foregoing, a disposition shall include any transfer, voluntary or involuntary, by the
Partnership or any Subsidiary in a foreclosure proceeding, pursuant to a deed in lieu of foreclosure, or in a bankruptcy proceeding. 
 Notwithstanding the foregoing, this Section 2.1 shall not apply to a voluntary, actual disposition by a Protected Partner of Units in connection with a merger or consolidation of the
Partnership pursuant to which (1) the Protected Partner is offered as consideration for the Units either cash or property treated as cash pursuant to Section 731 of the Code (“Cash Consideration”) or partnership interests and the
receipt of such partnership interests would not result in the recognition of gain for federal income tax purposes by the Protected Partner (“Partnership Interest Consideration”); (2) the Protected Partner has the right to elect to
receive solely Partnership Interest Consideration in exchange for his Units, and the continuing partnership has agreed in writing to assume the obligations of the Partnership under this Agreement; (3) no Protected Gain is recognized by the
Partnership as a result of any partner of the Partnership receiving Cash Consideration; and (4) the Protected Partner elects or is deemed to elect to receive solely Cash Consideration. 

(b) Notwithstanding the restriction set forth in this Section 2.1, the Partnership and any Subsidiary may dispose of any Gain
Limitation Property (or any interest therein) if such disposition qualifies as a “like-kind exchange” under Section 1031 of the Code, or an involuntary conversion under Section 1033 of the Code, or other transaction (including,
but not limited to, a contribution of property to any entity that qualifies for the non-recognition of gain under Section 721 or Section 351 of the Code, or a merger or consolidation of the Partnership with or into another entity that
qualifies for taxation as a “partnership” for federal income tax purposes (a “Successor Partnership”)) that, as to each of the foregoing, does not result in the recognition of any taxable income or gain to any Protected Partner
with respect to any of the Units; provided, however, that in the case of a “like-kind exchange,” under Section 1031 of the Code if such exchange is with a “related party” within the meaning of
Section 1031(f)(3) of the Code, any direct or indirect disposition by such related party of the Gain Limitation Property or any other transaction prior to the expiration of the two (2) year period following such exchange that would cause
Section 1031(f)(1) of the Code to apply with respect to such Gain Limitation Property (including by reason of the application of Section 1031(f)(4) of the Code) shall be considered a violation of this Section 2.1 by the
Partnership. 

  
 4 

  
 ARTICLE 3

 NOTIFICATION OF REDUCTION OF LIABILITIES; COOPERATION REGARDING 

SPECIAL ALLOCATION OF LIABILITIES 
 3.1 Notification Requirement. During the Tax Protection Period, the Partnership shall provide prior written notice to a Protected Partner if the Partnership intends to repay, retire, refinance or
otherwise reduce (other than scheduled amortization) the amount of liabilities with respect to a Gain Limitation Property in a manner that would cause a Protected Partner to recognize gain or loss for federal income tax purposes. 

3.2 Special Allocation of Liabilities. If the Partnership provides notice to a Protected Partner pursuant to
Section 3.1, the Partnership shall cooperate with the Protected Partner to arrange a special allocation of liabilities of the Partnership to the Protected Partner in such amount or amounts so as to increase the amount of partnership
liabilities allocated to such Protected Partner for purposes of Section 752 of the Code by an amount necessary to prevent the Protected Partner from recognizing gain or loss for federal income tax purposes as a result of the intended repayment,
retirement, refinancing or other reduction (other than scheduled amortization) in the amount of liabilities with respect to a Gain Limitation Property, including, without limitation, offering to the Protected Partner the opportunity either
(i) to enter into a “bottom dollar guarantee” of certain liabilities of the Partnership (substantially in the form set forth in Schedule 3.2(b)) in the amount of the Minimum Liability Amount (determined as of the Closing Date)
pursuant to which the lender for the guaranteed liability is required to pursue all other collateral and security for the guaranteed liability (other than any “bottom dollar guarantees”) prior to seeking to collect on such a guarantee, and
the lender shall have recourse against the guarantee only if, and solely to the extent that, the total amount recovered by the lender with respect to the guaranteed liability after the lender has exhausted its remedies is less than the aggregate of
the guaranteed amounts with respect to such liability, and the maximum aggregate liability of each partner for all guaranteed liabilities shall be limited to the amount actually guaranteed by such partner or (ii) to enter into a “deficit
restoration obligation” pursuant to which the Protected Partner would enter into a written obligation to restore part or all of its deficit capital account in the Partnership upon the occurrence of certain events (which written obligation may
provide for an indemnity in favor of the REIT as general partner of the Partnership). In order to minimize the need to specially allocate liabilities of the Partnership pursuant to the preceding sentence, the Partnership will use the additional
method under Treasury Regulations Section 1.752-3(a)(3) to allocate Nonrecourse Liabilities considered secured by a Gain Limitation Property to the Protected Partner to the extent that the “built-in gain” with respect to those
properties exceeds the amount of the Nonrecourse Liabilities considered secured by such Gain Limitation Property and allocated to the Protected Partner under Treasury Regulations Section 1.752-3(a)(2). 

  
 5 

  
 ARTICLE 4

 REMEDIES FOR BREACH 
 4.1 Monetary Damages. In the event that the Partnership breaches its obligations set forth in Article 2 or Article 3, with respect to a Protected Partner the Protected Partner’s sole right
shall be to receive from the Partnership, and the Partnership shall pay to such Protected Partner as damages, an amount equal to: 
  

	 	(a)	in the case of a violation of Article 2, the aggregate federal state, and local income taxes incurred by the Protected Partner or an Indirect Owner with respect to the
Protected Gain that is allocable to such Protected Partner under the Partnership Agreement as a result of the disposition of the Gain Limitation Property; and 

 

	 	(b)	in the case of a violation of Article 3, the aggregate federal, state and local income taxes incurred by the Protected Partner or an Indirect Owner as a result of the
income or gain allocated to, or otherwise recognized by, such Protected Partner with respect to its Units by reason of such breach. 

 For purposes of computing the amount of federal, state, and local income taxes required to be paid by a Protected Partner (or Indirect Owner), (i) any deduction for state income taxes payable as a
result thereof actually allowed in computing federal income taxes shall be taken into account, and (ii) a Protected Partner’s (or Indirect Owner’s) tax liability shall be computed using the highest federal, state and local marginal
income tax rates that would be applicable to such Protected Partner’s (or Indirect Owner’s) taxable income (taking into account the character and type of such income or gain) for the year with respect to which the taxes must be paid,
without regard to any deductions, losses or credits that may be available to such Protected Partner (or Indirect Owner) that would reduce or offset its actual taxable income or actual tax liability if such deductions, losses or credits could be
utilized by the Protected Partner (or Indirect Owner) to offset other income, gain or taxes of the Protected Partner (or Indirect Owner), either in the current year, in earlier years, or in later years). 

4.2 Process for Determining Damages. If the Partnership has breached or violated any of the covenants set forth in Article 2 or
Article 3 (or a Protected Partner asserts that the Partnership has breached or violated any of the covenants set forth in Article 2 or Article 3), the Partnership and the Protected Partner (or Indirect Owner) agree to negotiate in good faith to
resolve any disagreements regarding any such breach or violation and the amount of damages, if any, payable to such Protected Partner (or Indirect Owner) under Section 4.1. If any such disagreement cannot be resolved by the Partnership
and such Protected Partner (or Indirect Owner) within sixty (60) days after the receipt of notice from the Partnership of such breach and the amount of income to be recognized by reason thereof (or, if applicable, receipt by the Partnership of
an assertion by a Protected Partner that the Partnership has breached or violated any of the covenants set forth in Article 2 or Article 3), the Partnership and the Protected Partner shall jointly retain a nationally recognized independent public
accounting firm (“an Accounting Firm”) to act as an arbitrator to resolve as expeditiously as possible all points of any such disagreement (including, without limitation, whether a breach of any of the covenants set forth Article 2 or
Article 3, has occurred and, if so, the amount of damages to which the Protected 

  
 6 

 
Partner is entitled as a result thereof, determined as set forth in Section 4.1). All determinations made by the Accounting Firm with respect to the resolution of any breach or
violation of any of the covenants set forth in Article 2 or Article 3 and the amount of damages payable to the Protected Partner under Section 4.1 shall be final, conclusive and binding on the Partnership and the Protected Partner. The
fees and expenses of any Accounting Firm incurred in connection with any such determination shall be shared equally by the Partnership and the Protected Partner, provided that if the amount determined by the Accounting Firm to be owed by the
Partnership to the Protected Partner is more than five percent (5%) higher than the amount proposed by the Partnership to be owed to such Protected Partner prior to the submission of the matter to the Accounting Firm, then all of the fees and
expenses of any Accounting Firm incurred in connection with any such determination shall be paid by the Partnership and if the amount determined by the Accounting Firm to be owed by the Partnership to the Protected Partner is more than five percent
(5%) less than the amount proposed by the Partnership to be owed to such Protected Partner prior to the submission of the matter to the Accounting Firm, then all of the fees and expenses of any Accounting Firm incurred in connection with any
such determination shall be paid by the Protected Partner. 
 4.3 Required Notices; Time for Payment. In the event that
there has been a breach of Article 2 or Article 3, the Partnership shall provide to each affected Protected Partner notice of the transaction or event giving rise to such breach not later than at such time as the Partnership provides to the
Protected Partners the IRS Schedule K-1’s to the Partnership’s federal income tax return. All payments required under this Article 4 to any Protected Partner shall be made to such Protected Partner on or before April 15 of the year
following the year in which the gain recognition event giving rise to such payment took place; provided that, if the Protected Partner is required to make estimated tax payments that would include such gain (taking into account all available
safe harbors), the Partnership shall make a payment to the Protected Partner on or before the due date for such estimated tax payment and such payment from the Partnership shall be in an amount that corresponds to the amount of the estimated tax
being paid by such Protected Partner at such time. In the event of a payment required after the date required pursuant to this Section 4.3, interest shall accrue on the aggregate amount required to be paid from such date to the date of
actual payment at a rate equal to the “prime rate” of interest, as published in the Wall Street Journal (or if no longer published there, as announced by Citibank) effective as of the date the payment is required to be made. 

ARTICLE 5 

SECTION 704(C) METHOD AND ALLOCATIONS 
 5.1 Application of “Traditional Method.” Notwithstanding any provision of the Partnership Agreement, the Partnership shall use the “traditional method” under Treasury
Regulations Section 1.704-3(b) for purposes of making all allocations under Section 704(c) of the Code with respect to any Gain Limitation Property. 
 ARTICLE 6 
 AMENDMENT OF THIS AGREEMENT; WAIVER OF CERTAIN PROVISIONS

 6.1 Amendment. This Agreement may not be amended, directly or indirectly (including by reason of a merger between
either the Partnership or the REIT and another entity) 

  
 7 

 
except by a written instrument signed by the REIT, the Partnership, and each of the Protected Partners to be subject to such amendment, except that the Partnership may amend Schedules
2.1(a) and 3.2(a) upon a person becoming a Protected Partner as a result of a transfer of Units. 
 6.2
Waiver. Notwithstanding the foregoing, upon written request by the Partnership, each Protected Partner, in its sole discretion, may waive the payment of any damages that is otherwise payable to such Protected Partner pursuant to Article 4
hereof. Such a waiver shall be effective only if obtained in writing from the affected Protected Partner. 
 ARTICLE 7

 MISCELLANEOUS 
 7.1 Additional Actions and Documents. Each of the parties hereto hereby agrees to take or cause to be taken such further actions, to execute, deliver, and file or cause to be executed, delivered
and filed such further documents, and will obtain such consents, as may be necessary or as may be reasonably requested in order to fully effectuate the purposes, terms and conditions of this Agreement. 

7.2 Assignment. No party hereto shall assign its or his rights or obligations under this Agreement, in whole or in part, except by
operation of law, without the prior written consent of the other parties hereto, and any such assignment contrary to the terms hereof shall be null and void and of no force and effect. 

7.3 Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the Protected Partners and
their respective successors and permitted assigns, whether so expressed or not. This Agreement shall be binding upon the REIT, the Partnership, and any entity that is a direct or indirect successor, whether by merger, transfer, spin-off or
otherwise, to all or substantially all of the assets of either the REIT or the Partnership (or any prior successor thereto as set forth in the preceding portion of this sentence), provided that none of the foregoing shall result in the
release of liability of the REIT and the Partnership hereunder. The REIT and the Partnership covenant with and for the benefit of the Protected Partners not to undertake any transfer of all or substantially all of the assets of either entity
(whether by merger, transfer, spin-off or otherwise) unless the transferee has acknowledged in writing and agreed in writing to be bound by this Agreement, provided that the foregoing shall not be deemed to permit any transaction otherwise
prohibited by this Agreement. 
 7.4 Modification; Waiver. No failure or delay on the part of any party hereto in
exercising any power or right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such a right or power, preclude any other or
further exercise thereof or the exercise of any other right or power. The rights and remedies of the parties hereunder are cumulative and not exclusive of any rights or remedies which they would otherwise have. No modification or waiver of any
provision of this Agreement, nor consent to any departure by any party therefrom, shall in any event be effective unless the same shall be in writing, and then such waiver or consent shall be effective only in the specific instance and for the
purpose for which given. No notice to or demand on any party in any case shall entitle such party to any other or further notice or demand in similar or other circumstances. 

  
 8 

  
 7.5 Representations
and Warranties Regarding Authority; Noncontravention. Each of the REIT and the Partnership has the requisite corporate or other (as the case may be) power and authority to enter into this Agreement and to perform its respective obligations
hereunder. The execution and delivery of this Agreement by each of the REIT and the Partnership and the performance of each of its respective obligations hereunder have been duly authorized by all necessary trust, partnership, or other (as the case
may be) action on the part of each of the REIT and the Partnership. This Agreement has been duly executed and delivered by each of the REIT and the Partnership and constitutes a valid and binding obligation of each of the REIT and the Partnership,
enforceable against each of the REIT and the Partnership in accordance with its terms, except as such enforcement may be limited by (i) applicable bankruptcy or insolvency laws (or other laws affecting creditors’ rights generally) or
(ii) general principles of equity. The execution and delivery of this Agreement by each of the REIT and the Partnership do not, and the performance by each of its respective obligations hereunder will not, conflict with, or result in any
violation of (i) the Partnership Agreement or (ii) any other agreement applicable to the REIT and/or the Partnership, other than, in the case of clause (ii), any such conflicts or violations that would not materially adversely affect the
performance by the Partnership and the REIT of their obligations hereunder. 
 7.6 Captions. The Article and Section
headings contained in this Agreement are inserted for convenience of reference only, shall not be deemed to be a part of this Agreement for any purpose, and shall not in any way define or affect the meaning, construction or scope of any of the
provisions hereof. 
 7.7 Notices. All notices and other communications given or made pursuant hereto shall be in
writing, shall be deemed to have been duly given or made as of the date delivered, mailed or transmitted, and shall be effective upon receipt, if delivered personally, mailed by registered or certified mail (postage prepaid, return receipt
requested) to the parties at the following addresses (or at such other address for a party as shall be specified by like changes of address) or sent by electronic transmission to the telecopier number specified below: 

 

	 	(i)	if to the Partnership or the REIT, to: 

 Richmond Honan Medical Properties, Inc. 
 975 Johnson Ferry Road,
Suite 450 
 Atlanta, Georgia 30342 

Attention: Kent Ohlsen 
 Telecopier No. (404) 255-6300 
  

	 	(ii)	if to a Protected Partner, to the address on file with the Partnership. 

 Each party may designate by notice in writing a new address to which any notice, demand, request or communication may thereafter be so given, served or sent. Each notice, demand, request, or communication
which shall be hand delivered, sent, mailed, telecopied or telexed in the manner described above, or which shall be delivered to a telegraph company, shall be 

  
 9 

 
deemed sufficiently given, served, sent, received or delivered for all purposes at such time as it is delivered to the addressee (with the return receipt, the delivery receipt, or (with respect
to a telecopy or telex) the answerback being deemed conclusive, but not exclusive, evidence of such delivery) or at such time as delivery is refused by the addressee upon presentation. 

7.8 Counterparts. This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same
agreement and each of which shall be deemed an original. 
 7.9 Governing Law. The interpretation and construction of
this Agreement, and all matters relating thereto, shall be governed by the laws of the State of Delaware, without regard to the choice of law provisions thereof. 
 7.10 Consent to Jurisdiction; Enforceability. 
 7.10.1 This Agreement and
the duties and obligations of the parties hereunder shall be enforceable against any of the parties in the courts of the State of Georgia. For such purpose, each party hereto and the Protected Partners hereby irrevocably submits to the nonexclusive
jurisdiction of such courts and agrees that all claims in respect of this Agreement may be heard and determined in any of such courts. 
 7.10.2 Each party hereto hereby irrevocably agrees that a final judgment of any of the courts specified above in any action or proceeding relating to this Agreement shall be conclusive and may be enforced
in other jurisdictions by suit on the judgment or in any other manner provided by law. 
 7.11 Severability. If any part
of any provision of this Agreement shall be invalid or unenforceable in any respect, such part shall be ineffective to the extent of such invalidity or unenforceability only, without in any way affecting the remaining parts of such provision or the
remaining provisions of this Agreement. 
 7.12 Costs of Disputes. Except as otherwise expressly set forth in this
Agreement, the nonprevailing party in any dispute arising hereunder shall bear and pay the costs and expenses (including, without limitation, reasonable attorneys’ fees and expenses) incurred by the prevailing party or parties in connection
with resolving such dispute. 
 7.13 Enforcement by Protected Partners. The Protected Partners are the beneficiaries of
this Agreement and shall be able to enforce this Agreement as they were parties to this Agreement. 

  
 10 

  
 IN WITNESS WHEREOF,
the REIT, the Partnership and the Merging Entity have caused this Agreement to be signed by their respective officers, general partners, or delegates thereunto duly authorized all as of the date first written above. 

 

			
	 RICHMOND HONAN MEDICAL PROPERTIES INC.,

	 a Maryland corporation

		
	 By:
	 	  

	 Name:
	 	
	 Title:
	 	

  

			
	 RICHMOND HONAN MEDICAL PROPERTIES LP,

	 a Delaware limited partnership

		
	 By:
	  	Richmond Honan Medical Properties Inc.,
		  	a Maryland corporation,
		  	its General Partner

  

					
	By:	  	  
	  	
		  	Name:	  	
		  	Title:	  	

  

			
	 RICHMOND 400, Ltd.,
 a Georgia limited partnership

		
	 By:
	    	RMMC Co.,
		    	a Georgia corporation,
		    	its General Partner

  

					
	 By:
	  	  
	  	
		  	Name:	  	
		  	Title:	  	

  
 11 

  
 SCHEDULES AND
EXHIBITS TO THE TAX PROTECTION AGREEMENT 
  

			
		
	Schedule 2.1(a)	 	List of Protected Partners
		
	Schedule 2.1(b)	 	Gain Limitation Properties and Estimated Initial Protected Gain for Protected Partners as a Group
		
	Schedule 3.2(a)	 	Minimum Liability Amount
		
	Schedule 3.2(b)	 	Form of Guarantee Agreement

  
 12 

  
 Schedule 2.1(a)

 List of Protected Partners 

  
 Schedule
2.1(b) */ 
 Gain Limitation Properties and 

Estimated Initial Protected Gain for Protected Partners as a Group 

 

			
	Name of Protected Property	  	Initial Protected Gain (Aggregate)
		
	975 Johnson Ferry Road, Atlanta, Georgia 30342	  	

  

	*/	The Company will endeavor in good faith to complete this schedule within 75 days after the Closing Date. 

  
 Schedule 3.2(a)

 Minimum Liability Amount 
  

			
	Protected Partner	  	Minimum Liability Amount
**/
	  	  	  
	  	  	  
	  	  	  
	  	  	  
	  	  	  
	  	  	  

  

	**/	The estimated “negative tax capital account” of a Partner in the Partnership on the closing date of the IPO as determined by the Partnership in its sole
discretion. 

  
 Schedule 3.2(b)

 Form of Guaranty 1/ 

GUARANTEE 

This Guarantee is made and entered into as of the     day of
            20    , by the persons listed on Exhibit A annexed hereto (the “Guarantors”) for the benefit of the
Lender set 
  
  

	1/	 This Form of the Guarantee Agreement is for Guaranteed Debt where the following conditions all are applicable: 

 

	 	(i)	there are no other guarantees in effect with respect to such Guaranteed Debt; 

 

	 	(ii)	the collateral securing such Guaranteed Debt is not collateral for any other indebtedness that is senior to or pari passu with such Guaranteed Debt;

  

	 	(iii)	no additional guarantees with respect to such Guaranteed Debt will be entered into during the applicable Tax Protection Period; 

 

	 	(iv)	the lender with respect to such Guaranteed Debt is not the Partnership, any Subsidiary or other entity in which the Partnership owns a direct or indirect interest, the
REIT, any other partner in the Partnership, or any person related to any partner in the Partnership as determined for purposes of Treasury Regulations Section 1.752-2; and 

 

	 	(v)	none of the REIT, nor any other partner in the Partnership, nor any person related to any partner in the Partnership as determined for purposes of Treasury Regulations
Section 1.752-2 shall have provided, or shall thereafter provide, collateral for, or otherwise shall have entered, or thereafter shall enter, into a relationship that would cause such person or entity to be considered to bear risk of loss with
respect to such Guaranteed Debt, as determined for purposes of Treasury Regulations Section 1.752-2. 

 If,
and to the extent that, one or more of these conditions is not applicable, appropriate changes to the attached Form of Guaranty will be required in order to cause the various conditions set forth in Article 3 of the Tax Protection Agreement to be
satisfied. 

 
forth on Exhibit B annexed hereto and made a part hereof (the “Lender,” which term shall include any person or entity who hereafter holds the Note (as
defined below) in accordance with the terms thereof). 
 RECITALS 

WHEREAS, the Lender has loaned to the borrower set forth on Exhibit B (the “Borrower”) the amount
set forth opposite such Lender’s name on Exhibit B, which loan (i) is evidenced by the promissory note described on Exhibit C hereto (the “Note”), (ii) has a current outstanding
balance in the amount set forth on Exhibit B annexed hereto, and (iii) is secured by a mortgage or deed of trust on the collateral described on Exhibit D annexed hereto (the “Deed of Trust,”
with the property and other assets securing such Deed of Trust referred to as the “Collateral”); 

WHEREAS, the Borrower is either Richmond Honan Medical Properties, LP, a Delaware limited partnership (the
“Partnership”), or a subsidiary of the Partnership in which the Partnership owns a 98% or greater interest in the Partnership; 
 WHEREAS, the Guarantors are limited partners in the Partnership; and 
 WHEREAS,
the Guarantors are executing and delivering this Guarantee to guarantee a portion of the Borrower’s payments with respect to the Note, subject to and otherwise in accordance with the terms and conditions hereinafter set forth. 

NOW THEREFORE, in consideration of the foregoing recitals and facts and other good and valuable consideration, the receipt and legal
sufficiency of which are hereby acknowledged, each of the Guarantors hereby agree as follows: 
 1. Guarantee and Performance
of Payment. 
 (a) The Guarantors hereby irrevocably and unconditionally guarantee the collection by the Lender of, and
hereby agree to pay to the Lender upon demand (following (1) foreclosure of the Deed of Trust, exercise of the powers of sale thereunder and/or acceptance by the Lender of a deed to the Collateral in lieu of foreclosure, and (2) the
exhaustion of the exercise of any and all remedies available to the Lender against the Borrower, including, without limitation, realizing upon the assets of the Borrower other than the Collateral against which the Lender may have recourse), an
amount equal to the excess, if any, of the Guaranteed Amount set forth on Exhibit B over the Lender Proceeds (as hereinafter defined) (which excess is referred to as the “Aggregate Guarantee Liability”). The amounts payable
by each Guarantor in respect of the guarantee obligations hereunder shall be in the same proportion as the dollar amounts listed next to such Guarantor’s name on Exhibit A attached hereto bears to the total Guaranteed Amount set
forth on Exhibit A, provided that, notwithstanding anything to the contrary contained in this Guarantee, each Guarantor’s aggregate obligation under this Guarantee shall be limited to the dollar amount set forth on
Exhibit A attached hereto next to such Guarantor’s name. The Guarantors’ obligations as set forth in this paragraph 1(a) are hereinafter referred to as the “Guaranteed Obligations.” 

  
 (b) For the purposes
of this Guarantee, the term “Lender Proceeds” shall mean the aggregate of (i) the Foreclosure Proceeds (as hereinafter defined) plus (ii) all amounts collected by the Lender from the Borrower (other than payments of
principal, interest or other amounts required to be paid by the Borrower to Lender under the terms of the Note that are paid by the Borrower to the Lender at a time when no default has occurred under the Note and is continuing) or realized by the
Lender from the sale of assets of the Borrower other than the Collateral. 
 (c) For the purposes of this Guarantee, the term
“Foreclosure Proceeds” shall have the applicable meaning set forth below with respect to the Collateral: 
  

	 	1.	If at least one bona fide third party unrelated to the Lender (and including, without limitation, any of the Guarantors) bids for such Collateral at a sale thereof,
conducted upon foreclosure of the related Deed of Trust or exercise of the power of sale thereunder, Foreclosure Proceeds shall mean the highest amount bid for such Collateral by the party that acquires title thereto (directly or through a nominee)
at or pursuant to such sale. For the purposes of determining such highest bid, amounts bid for the Collateral by the Lender shall be taken into account notwithstanding the fact that such bids may constitute credit bids which offset against the
amount due to the Lender under the Note. 

  

	 	2.	If there is no such unrelated third-party at such sale of the Collateral so that the only bidder at such sale is the Lender or its designee, the Foreclosure Proceeds
shall be deemed to be fair market value (the “Fair Market Value”) of the Collateral as of the date of the foreclosure sale, as such Fair Market Value shall be mutually agreed upon by the Lender and the Guarantor or determined
pursuant to subparagraph 1(d). 

  

	 	3.	If the Lender receives and accepts a deed to the Collateral in lieu of foreclosure in partial satisfaction of the Borrower’s obligations under the Note, the
Foreclosure Proceeds shall be deemed to be the Fair Market Value of such Collateral as of the date of delivery of the deed-in-lieu of foreclosure, as such Fair Market Value shall be mutually agreed upon by the Lender and the Guarantor or determined
pursuant to subparagraph 1(d). 

 (d) Fair Market Value of the Collateral (or any item thereof) shall be the price
at which a willing seller not compelled to sell would sell such Collateral, and a willing buyer not compelled to buy would purchase such Collateral, free and clear of all mortgages but subject to all leases and reciprocal easements and operating
agreements. If the Lender and the Guarantor are unable to agree upon the Fair Market Value of any Collateral in accordance with subparagraphs 1(c)2. or 3. above, as applicable, within twenty (20) days after the date of the foreclosure sale or
the delivery of the deed-in-lieu of foreclosure, as applicable, relating to such Collateral, either party may have the Fair Market Value of such Collateral determined by appraisal by appointing an appraiser having the qualifications set forth below
to determine the same and by notifying the other party of such appointment within twenty (20) days after the expiration of such twenty (20) day period. If the other party shall fail to notify the first party, within twenty (20) days
after its receipt of notice of the appointment by the first party, of the appointment by the other party of an appraiser having the qualifications set forth below, the 

 
appraiser appointed by the first party shall alone make the determination of such Fair Market Value. Appraisers appointed by the parties shall be members of the Appraisal Institute (MAI) and
shall have at least ten years’ experience in the valuation of properties similar to the Collateral being valued in the greater metropolitan area in which such Collateral is located. If each party shall appoint an appraiser having the aforesaid
qualifications and if such appraisers cannot, within thirty (30) days after the appointment of the second appraiser, agree upon the determination hereinabove required, then they shall select a third appraiser which third appraiser shall have
the aforesaid qualifications, and if they fail so to do within forty (40) days after the appointment of the second appraiser they shall notify the parties hereto, and either party shall thereafter have the right, on notice to the other, to
apply for the appointment of a third appraiser to the chapter of the American Arbitration Association or its successor organization located in the metropolitan area in which the Collateral is located or to which the Collateral is proximate or if no
such chapter is located in such metropolitan area, in the metropolitan area closest to the Collateral in which such a chapter is located. Each appraiser shall render its decision as to the Fair Market Value of the Collateral in question within
thirty (30) days after the appointment of the third appraiser and shall furnish a copy thereof to the Lender and the Guarantor. The Fair Market Value of the Collateral shall then be calculated as the average of (i) the Fair Market Value
determined by the third appraiser and (ii) whichever of the Fair Market Values determined by the first two appraisers is closer to the Fair Market Value determined by the third appraiser; provided, however, that if the Fair Market
Value determined by the third appraiser is higher or lower than both Fair Market Values determined by the first two appraisers, such Fair Market Value determined by the third appraiser shall be disregarded and the Fair Market Value of the Collateral
shall then be calculated as the average of the Fair Market Value determined by the first two appraisers. The Fair Market Value of a Property, as so determined, shall be binding and conclusive upon the Lender and the Guarantors. Guarantors shall bear
the cost of its own appraiser and, subject to subparagraph 1(e), shall bear all reasonable costs of appointing, and the expenses of, any other appraiser appointed pursuant to this subparagraph (1)(d). 

(e) Notwithstanding anything in the preceding subparagraphs of this paragraph 1, (i) in no event shall the aggregate amount
required to be paid pursuant to this Guarantee by the Guarantors as a group with respect to all defaults under the Note and the Deed of Trust securing the obligations thereunder exceed the Guaranteed Amount set forth on Exhibit B
hereto, and (ii) the aggregate obligation of each Guarantor hereunder with respect to the Guaranteed Obligation shall be limited to the lesser of (I) the product of (w) the Individual Guarantee Percentage for such Guarantor
set forth on Exhibit A hereto multiplied by (x) the Guaranteed Amount, or (II) the product of (y) such Guarantor’s Individual Guarantee Percentage multiplied by (z) the Aggregate Guarantee Liability.

 (f) In confirmation of the foregoing, and without limitation, the Lender must first exhaust all of its rights and remedies
against all property of the Borrower as to which the Lender has (or may have) a right of recourse, including, without limitation, the institution and prosecution to completion of appropriate foreclosure proceedings under the Deed of Trust, before
exercising any right or remedy or making any claim, under this Guarantee. 
 (g) The obligations under this Guarantee shall be
personal to each Guarantor and shall not be affected by any transfer of all or any part of a Guarantor’s interests in the Partnership; provided, however, that if a Guarantor has disposed of all of its equity interests in

 
the Partnership, the obligations of such Guarantor under this Guarantee shall terminate 12 months after the date of such disposition (the “Termination Date”) provided (i) the
Guarantor notifies the Lender that it is terminating its obligations under this Guarantee as of the Termination Date and (ii) the fair market value of the Collateral exceeds the outstanding balance of the Note, including accrued and unpaid
interest, as of the Termination Date. Further, no Guarantor shall have the right to recover from the Borrower any amounts such Guarantor pays pursuant to this Guarantee (except and only to the extent that the amount paid to the Lender by such
Guarantor exceeds the amount required to be paid by such Guarantor under the terms of this Guarantee). 
 (h) The obligations of
any Guarantor who is an individual as a Guarantor hereunder shall terminate with respect to such Guarantor one week after the death of such Guarantor if, as a result of the death of such Guarantor, all property held by the Guarantor on the date of
death would have a basis for federal income tax purposes equal to the fair market value of such property on such date (unless a later date were to be elected by the executor of the Guarantor’s estate in accordance with the applicable provisions
of the Internal Revenue Code). 
 2. Intent to Benefit Lender. This Guarantee is expressly for the benefit of the Lender.
The Guarantors intend that the Lender shall have the right to enforce the obligations of the Guarantors hereunder separately and independently of the Borrower, subject to the provisions of paragraph 1 hereof, without any requirement whatsoever of
resort by the Lender to any other party. The Lender’s rights to enforce the obligations of the Guarantors hereunder are material elements of this Guarantee. This Guarantee shall not be modified, amended or terminated (other than as specifically
provided herein) without the written consent of the Lender. The Borrower shall furnish a copy of this Guarantee to the Lender contemporaneously with its execution. 
 3. Waivers. Each Guarantor intends to bear the ultimate economic responsibility for the payment hereof of the Guaranteed Obligations to the extent set forth in Paragraph 1 above. Pursuant to such
intent: 
 (a) Except as expressly set forth in Paragraph 1 above, each Guarantor expressly waives any right (pursuant to any
law, rule, arrangement or relationship) to compel the Lender, or any subsequent holder of the Note or any beneficiary of the Deed of Trust to sue or enforce payment thereof or pursue any other remedy in the power of the Borrower, the Lender or any
subsequent holder of the Note or any beneficiary of the Deed of Trust whatsoever, and failure of the Borrower or the Lender or any subsequent holder of the Note or any beneficiary of the Deed of Trust to do so shall not exonerate, release or
discharge a Guarantor from its absolute unconditional obligations under this Guarantee. Each Guarantor hereby binds and obligates itself, and its permitted successors and assignees, for performance of the Guaranteed Obligations according to the
terms hereof, whether or not the Guaranteed Obligations or any portion thereof are valid now or hereafter enforceable against the Borrower or shall have been incurred in compliance with any of the conditions applicable thereto, subject, however, in
all respects to the Guarantee Limit and the other limitations set forth in paragraph 1. 
 (b) Each Guarantor expressly
waives any right (pursuant to any law, rule, arrangement, or relationship) to compel any other person (including, but not limited to, the Borrower, the Partnership, any subsidiary of the Partnership or the Borrower, or any other

 
partner or affiliate of the Partnership or the Borrower) to reimburse or indemnify such Guarantor for all or any portion of amounts paid by such Guarantor pursuant to this Guarantee to the extent
such amounts do not exceed the amounts required to be paid by such Guarantor pursuant to paragraph 1 hereof (taking into account the limitations set forth therein). 
 (c) Except as expressly set forth in Paragraph 1 above, if and only to the extent that the Borrower has made similar waivers under the Note or the Deed of Trust, each Guarantor expressly waives:
(i) the defense of the statute of limitations in any action hereunder or for the collection or performance of the Note or the Deed of Trust; (ii) any defense that may arise by reason of: the incapacity, or lack of authority of the
Borrower, the revocation or repudiation hereof by such Guarantor, the revocation or repudiation of the Note or the Deed of Trust by the Borrower, the failure of the Lender to file or enforce a claim against the estate (either in administration,
bankruptcy or any other proceeding) of the Borrower; the unenforceability in whole or in part of the Note, the Deed of Trust or any other document or instrument related thereto; the Lender’s election, in any proceeding by or against the
Borrower under the federal Bankruptcy Code, of the application of Section 1111(b)(2) of the federal Bankruptcy Code; or any borrowing or grant of a security interest under Section 364 of the federal Bankruptcy Code; (iii) presentment,
demand for payment, protest, notice of discharge, notice of acceptance of this Guarantee or occurrence of, or any default in connection with, the Note or the Deed of Trust, and indulgences and notices of any other kind whatsoever, including, without
limitation, notice of the disposition of any collateral for the Note; (iv) any defense based upon an election of remedies (including, if available, an election to proceed by non-judicial foreclosure) or other action or omission by the Lender or
any other person or entity which destroys or otherwise impairs any indemnification, contribution or subrogation rights of such Guarantor or the right of such Guarantor, if any, to proceed against the Borrower for reimbursement, or any combination
thereof; (v) subject to Paragraph 4 below, any defense based upon any taking, modification or release of any collateral or guarantees for the Note, or any failure to create or perfect any security interest in, or the taking of or failure to
take any other action with respect to any collateral securing payment or performance of the Note; (vi) any rights or defenses based upon any right to offset or claimed offset by such Guarantor against any indebtedness or obligation now or
hereafter owed to such Guarantor by the Borrower; or (vii) any rights or defenses based upon any rights or defenses of the Borrower to the Note or the Deed of Trust (including, without limitation, the failure or value of consideration, any
statute of limitations, accord and satisfaction, and the insolvency of the Borrower); it being intended, except as expressly set forth in Paragraph 1 above, that such Guarantor shall remain liable hereunder, to the extent set forth herein,
notwithstanding any act, omission or thing which might otherwise operate as a legal or equitable discharge of any of such Guarantor or of the Borrower. 
 4. Amendment of Note and Deed of Trust. Without in any manner limiting the generality of the foregoing, the Lender or any subsequent holder of the Note or beneficiary of the Deed of Trust may, from
time to time, without notice to or consent of the Guarantors, agree to any amendment, waiver, modification or alteration of the Note or the Deed of Trust relating to the Borrower and its rights and obligations thereunder (including, without
limitation, renewal, waiver or variation of the maturity of the indebtedness evidenced by the Note, increase or reduction of the rate of interest payable under the Note, release, substitution or addition of any Guarantor or endorser and acceptance
or release of any security for the Note), it being understood and agreed by the Lender, however, that the Guarantor’s obligations hereunder are 

 
subject, in all events, to the limitations set forth in Paragraph 1; provided that (i) in the event that the Lender consents to the release of any Collateral securing the Note
pursuant to the Deed of Trust, the Guaranteed Amount shall be reduced by the Fair Market Value of such Collateral on the date of such release (determined as set forth in Section 1(d)); and (ii) upon any material change to the Note or the
Deed of Trust, including, without limitation, the maturity date or the interest rate of the Note, or upon any release or substitution of any Collateral securing the Note, within thirty (30) days of any Guarantor’s receipt of actual notice
of such event, subject to the following sentence, such Guarantor may elect to terminate such Guarantor’s obligations under this Guarantee by written notice to the Lender. Such termination shall take effect on the 31st day following such actual
notice, provided that no default under the Guaranteed Obligation has occurred and is then continuing. 
 5.
Termination of Guarantee. Subject to Paragraph 4, this Guarantee is irrevocable as to any and all of the Guaranteed Obligations. 
 6. Independent Obligations. Except as expressly set forth in Paragraph 1, the obligations of each Guarantor hereunder are independent of the obligations of the Borrower, and a separate action or
actions may be brought by a Lender against the Guarantors, whether or not actions are brought against the Borrower. Each Guarantor expressly waives any and all rights of subrogation, reimbursement, indemnity, exoneration, contribution or any other
claim which such Guarantor may now or hereafter have against the Borrower, or any other person directly or contingently liable for the payment or performance of the Note and the Deed of Trust arising from the existence or performance of this
Guarantee (including, but not limited to, the Partnership, Richmond Honan Medical Properties, Inc., or any other partner of the Partnership) (except and only to the extent that a Guarantor makes a payment to the Lender in excess of the amount
required to be paid under paragraph 1 and the limitations set forth therein). 
 7. Understanding With Respect to
Waivers. Each Guarantor warrants and represents that each of the waivers set forth above are made with full knowledge of their significance and consequences, and that under the circumstances, the waivers are reasonable and not contrary to public
policy or law. If any of said waivers are determined to be contrary to any applicable law or public policy, such waiver shall be effective only to the maximum extent permitted by law. 

8. No Assignment. No Guarantor shall be entitled to assign his or her rights or obligations under this Guarantee to any
other person without the written consent of the Lender. 
 9. Entire Agreement. The parties agree that this
Guarantee contains the entire understanding and agreement between them with respect to the subject matter hereof and cannot be amended, modified or superseded, except by an agreement in writing signed by the parties. 

  
 10. Notices.
Any notice given pursuant to this Guarantee shall be in writing and shall be deemed given when delivered personally, or sent by registered or certified mail, postage prepaid, as follows: 

If to the Partnership: 
 Richmond Honan Medical Properties Inc. 
 975 Johnson Ferry Road

 Suite 450 
 Atlanta, GA 30342 
 Attention: Kent Ohlsen 

Facsimile: (404) 255-6300 
 or to such other address with respect to which notice is subsequently provided in the manner set forth above; and 
 If to a Guarantor, to the address set forth on Exhibit A hereto, or to such other address with respect to which notice is subsequently provided in the manner set forth above. 

11. Applicable Law. This Guarantee shall be governed by, interpreted under and construed in accordance with the laws of the State
of Delaware without reference to its choice of law provisions. 
 12. Consent to Jurisdiction; Enforceability 

(a) This Guarantee and the duties and obligations of the parties hereto shall be enforceable against each Guarantor in the courts of the
State of Georgia. For such purpose, each Guarantor hereby irrevocably submits to the nonexclusive jurisdiction of such courts and agrees that all claims in respect of this Guarantee may be heard and determined in any of such courts. 

(b) Each Guarantor hereby irrevocably agrees that a final judgment of any of the courts specified above in any action or proceeding
relating to this Guarantee shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. 
 13. Condition of Borrower. Each Guarantor is fully aware of the financial condition of the Borrower and is executing and delivering this Guarantee based solely upon its own independent
investigation of all matters pertinent hereto and is not relying in any manner upon any representation or statement of the Lender or the Borrower. Each Guarantor represents and warrants that it is in a position to obtain, and hereby assumes full
responsibility for obtaining, any additional information concerning the Borrower’s financial conditions and any other matter pertinent hereto as it may desire, and it is not relying upon or expecting the Lender to furnish to it any information
now or hereafter in the Lender’s possession concerning the same. By executing this Guarantee, each Guarantor knowingly accepts the full range of risks encompassed within a contract of this type, which risks it acknowledges. 

14. Expenses. Each Guarantor agrees that, promptly after receiving Lender’s notice therefor, such Guarantor shall reimburse
Lender, subject to the limitation set forth in subparagraph 1(e) and to the extent that such reimbursement is not made by Borrower, for all reasonable expenses (including, without limitation, reasonable attorneys fees and disbursements) incurred by
Lender in connection with the collection of the Guaranteed Obligations or any portion thereof or with the enforcement of this Guarantee. 

  
 IN WITNESS WHEREOF,
the undersigned Guarantors set forth on Exhibit A hereto have executed this Guarantee as of the date first set forth above. 
  

			
	 GUARANTORS SET FORTH ON
 EXHIBIT A HERETO:

		
	 By:
	 	  

		
	 By:
	 	  

		
	 By:
	 	  

		
	 By:
	 	  

		
	 By:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}]]